→
Investors should consider the various metrics and recent performance trends when evaluating AbbVie.
AbbVie Inc. has a market capitalization of $454.5B and a current price of $256.35, reflecting a decrease of 1.49% from the previous close of $260.21. The company has recorded an 8.57% revenue growth year-over-year, while EPS growth has declined by 1.26%. The P/E ratio stands at 108.62, and the dividend yield is 2.56%. The stock's 52-week range is between $190.75 and $267.48.
Some investors highlight AbbVie's 8.57% revenue growth year-over-year as a positive sign of its ability to expand despite challenges. Additionally, the stock is currently yielding a dividend of 2.56%, which may appeal to income-focused investors.
Conversely, AbbVie's P/E ratio of 108.62 suggests a high valuation relative to earnings, raising concerns about sustainability. The decline in EPS by 1.26% year-over-year and negative ROE of -129.24% could signal potential underlying issues in profitability.
Want AI analysis of your entire portfolio?
Helm Terminal connects to your brokerage, analyzes every holding, and delivers actionable intelligence weekly. Free to start.
Get started freeHelm provides financial data for informational purposes only. This is not financial, investment, or tax advice. Consult a qualified professional before making financial decisions.
Watch my tickers
Get an email when something changes on your tickers: the exact quote, dated and sourced. No account, no brokerage connection, unsubscribe anytime.
AbbVie Inc. has a market capitalization of $454.5B and a current price of $256.35, reflecting a decrease of 1.49% from the previous close of $260.21. The company has recorded an 8.57% revenue growth year-over-year, while EPS growth has declined by 1.26%. The P/E ratio stands at 108.62, and the dividend yield is 2.56%. The stock's 52-week range is between $190.75 and $267.48.
Conversely, AbbVie's P/E ratio of 108.62 suggests a high valuation relative to earnings, raising concerns about sustainability. The decline in EPS by 1.26% year-over-year and negative ROE of -129.24% could signal potential underlying issues in profitability.
Some investors highlight AbbVie's 8.57% revenue growth year-over-year as a positive sign of its ability to expand despite challenges. Additionally, the stock is currently yielding a dividend of 2.56%, which may appeal to income-focused investors.
Some investors highlight AbbVie's 8.57% revenue growth year-over-year as a positive sign of its ability to expand despite challenges. Additionally, the stock is currently yielding a dividend of 2.56%, which may appeal to income-focused investors. Conversely, AbbVie's P/E ratio of 108.62 suggests a high valuation relative to earnings, raising concerns about sustainability. The decline in EPS by 1.26% year-over-year and negative ROE of -129.24% could signal potential underlying issues in profitability.
AbbVie Inc. has a market capitalization of $454.5B and a current price of $256.35, reflecting a decrease of 1.49% from the previous close of $260.21. The company has recorded an 8.57% revenue growth year-over-year, while EPS growth has declined by 1.26%. The P/E ratio stands at 108.62, and the dividend yield is 2.56%. The stock's 52-week range is between $190.75 and $267.48.
Helm's analysis is generated by an AI model from live market data. It identifies risk signals, opportunities, and key metrics based on current fundamentals, recent price action, and analyst consensus. It does not execute trades, issue certified investment advice, or predict future prices.
Not financial advice. Informational use only. AI-generated content may contain errors. Consult a licensed financial advisor before making investment decisions. Helm Terminal is not registered as an investment advisor.
Helm Terminal offers free AI-powered stock analysis for ABBV at helmterminal.dev/analyze/ABBV, updated continuously during US market hours. No signup required.